So one ongoing question in the field is to identify the phenotypes, the subgroups of people who may be more responsive to these medications. Other challenges include patient adherence to treatment, which 20 percent of physicians cited as a challenge, and side effect management, which 18 percent of physicians cited as a challenge
Yet, students confuse which drug causes which toxicity and which antidote to use
Microdosing often requires more hands-on guidance, because results are subtle and happen gradually, adds Class
Goyal and Thirugnanam report no relevant conflicts of interest.
And so, that's where if there is not more investment being made over the next few years, there could potentially [be] a bottleneck emerging for the generic companies.Terence, while semaglutide generics will definitely represent a challenge for the existing branded version of this GLP-1, there are some insights in these emerging dynamics that suggest that tirzepatide, the other GLP-1, could be less at risk